Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Seer, Inc.NASDAQ: SEER

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital grows, but more slowly than its trailing trend

Q1 FY2026 change in working capital of $4.73M (cash outflow) rose 297.3% year over year, behind the +8308.2% change in trailing-twelve-month change in working capital. Sequentially, it rose 961.0% from the prior quarter. Over 3 fiscal years it compounded at -56.6% a year.

Context

  • Change in working capital amounted to 3.6% of revenue in FY2025, up 2.6 pp from a year earlier.
  • Change in working capital grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +297.3% toward the trailing-twelve-month pace of +8308.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.73M+961.0% QoQ
Last fiscal yearDec 2025
-$579K+302.1% YoY
LTMMar 2026
-$4.12M+8308.2% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+297.3%——
1 year+302.1%——
3-year CAGR-56.6%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(579K) USD
Year-over-year change
-302.1%

Change in Working Capital vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8308.2% is the highest of 19, against a peer median of -15.5%.
  • Change in working capital amounts to 27.4% of revenue for SEER, versus a peer median of 110.0%.
SEER Competitors
Change in Working Capital for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$89.59M USD+1482.8%+62.7%208.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$50.82M USD+271.7%+18.4%7.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$31.04M USD-3.9%—110.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$23.74M USD+149.1%+20.4%68.1%
PEPGPepGen Inc.LTM Mar 2026$13.38M USD-256.4%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$12.58M USD+237.9%+8.0%—
SANASana Biotechnology, Inc.LTM Mar 2026$6.99M USD+52.5%——
QSIQuantum-Si incorporatedLTM Mar 2026$6.69M USD-276.3%—361.1%
SEERSeer, Inc.LTM Mar 2026$4.12M USD+8308.2%-56.6%27.4%
NKTXNkarta, Inc.LTM Mar 2026$3.15M USD-65.8%——
PHVSPharvaris N.V.LTM Sep 2026€2.93M EUR-56.1%-3.1%—
KYMRKymera Therapeutics, Inc.LTM Jun 2026$2.13M USD-90.0%—2.0%
STTKShattuck Labs, Inc.LTM Mar 2026$1.73M USD-162.8%-44.0%172.9%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$1.68M USD-27.0%-64.7%—
MOLNMolecular Partners AGLTM Mar 2026CHF 1.53M CHF+140.6%——
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$1.47M USD+116.1%+52.4%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.42M USD-84.9%-50.6%4593.5%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$974K USD-159.1%+130.6%—
MNOVMediciNova, Inc.LTM Mar 2026$379.53K USD+144.6%+51.6%63.6%
Peer median (excluding SEER) —-15.5%+18.4%110.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.